Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
2024-12-24
IDOPRESS
BOSTON,Dec. 20,2024 -- Medicilon,a leading preclinical contract research organization (CRO),has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development,Dr. Xu will lead Medicilon's technological innovation and global expansion,strengthening its capabilities to deliver cutting-edge R&D solutions.
Dr. Lilly Xu
Dr. Xu,who holds a Ph.D. in Biology from St Louis University,is a recognized expert in pharmacokinetics,toxicology,and drug metabolism. She has successfully led numerous global drug development programs from early discovery through clinical stages and held leadership roles at major pharmaceutical and biotech companies,including Pharmaron,Icagen,Purdue Pharma,Sanofi,and Amgen.
"We are thrilled to welcome Dr. Xu during this pivotal time in Medicilon's growth," said Dr. Chunlin Chen,Founder and CEO of Medicilon. "Her extensive expertise and global perspective align with our vision of driving innovation and advancing our international presence."
Dr. Xu added,"I'm honored to join Medicilon's forward-thinking team. I look forward to contributing to platform innovation,accelerating the transition of research into clinical breakthroughs,and achieving milestones that will benefit our global clients and their patients."
Medicilon continues to expand its advanced research platforms,including nucleic acids,ADCs,PROTACs,antibodies,and cell and gene therapies,reinforcing its position as a leader in preclinical drug development.
Website: https://www.medicilon.com/
Newest
-
Jewellery & Gem ASEAN Bangkok (JGAB) 2025: Connecting ASEAN's Gem and Jewellery Business to the Global Market
-
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
-
Acer Reports FY2024 Net Income of NT$5.54 Billion and NT$1.7 Cash Dividend Per Share
-
Ping An #1 in Brand Finance's Global Insurance Brand Value for 9th Year, Brand Value Reaches $33.6 Billion